Open Nav

Please submit your session questions in advance at

R. John Glasspool

Research Affiliate and Senior Advisor, FoCUS Center for Biomedical Innovation: NEWDIGS

Massachusetts Institute of Technology

John Glasspool is a member of the Board of Directors of Dalcor Corporation. He was formerly the Executive Vice President, Head of Corporate Strategy and Customer Operations at Baxalta Incorporated, formerly Baxter BioScience. Prior to joining Baxter in August 2012, John was Head Region Europe and Novartis Vaccines & Diagnostics (V&D), a member of the V&D Executive Committee. John served as a board member, Vice President and President of the European Vaccine manufacturers (EVM), from 2010 until December 2012. Previously, John was Head of Global Pricing & Market Access, and Head of Global Commercial Operations in Novartis Pharma, where he led the functions in embedding the needs of customers and consumers for brands at all stages of their lifecycle -- development, launch and in market. John joined Novartis Head of Marketing for NeuroScience. He was promoted to Global Head CardioVascular & Metabolism Business Franchise in 2006, during which time he grew the franchise sales from $4.9 Bn in 2004 to $6.7 Bn over a three-year period. Before joining Novartis, John worked for J&J in Pharmaceuticals and Consumer, launching products in the Europe, US, and for J&J Corporate in Global Strategic Marketing. John held a number of positions with J&J during his career there including hospital sales, project and product manager, before becoming the Neurology Business Head responsible for marketing & sales and then Neurology European Business Director. Prior to working at J&J, John worked at a small startup company selling ethical products to GP's and a range of over the counter products to pharmacies. Before joining the pharmaceutical industry, John owned a restaurant and small hotel. While always holding commercial roles, John has been granted 2 patents. One is in neuroscience on "statin therapy for enhancing cognitive maintenance" (EP 1 492 539 B1) by European Patent Office on 28 June 2003. This patent relates to a method of treating dementia as a result of Alzheimer's Disease, or a memory disorder. The other one is in cardiovascular on the "use of iron chelator for the treatment of myocardial infarction" by World Intellectual Property Organization on 20 November 2008.

This speaker's sessions: